Shanghai-based CataX AI has raised RMB 40 million in a seed round from Qiming Venture Partners, which incubated the startup and was the sole investor. CataX AI plans to license or co-develop drug candidates at the preclinical or early clinical stage and advance them through clinical proof of concept.
The company calls its operating model “Clinical-of-One.” A clinical lead oversees each program with support from specialists and AI agents that review research, draft documents and process data. Human experts make key decisions, and the company aims to reuse what it learns across programs. Founder and CEO Wang Zilong has a background in clinical medicine and AI research at Microsoft Research Asia, while co-founder Jiang Zhemin has more than 15 years of clinical development experience. [TechNode reporting]
